Infant nutrition for improving fatty acid composition of brain membranes

Patent metadata

Field	Value
Publication number	US-9474764-B2
Application number	US-201113635389-A
Country	US
Kind code	B2
Filing date	Mar 17, 2011
Priority date	Mar 17, 2010
Publication date	Oct 25, 2016
Grant date	Oct 25, 2016

Abstract

The present invention relates to infant nutrition, in particular to infant nutrition comprising special lipid globules for improvement of the fatty acid composition in brain membranes.

First claim

The invention claimed is:

1. A method for increasing brain membrane n3 LC-PUFA and/or brain membrane DHA in a human subject, the method comprising administering to the human subject 80 to 2500 ml daily for at least 5 days a nutritional composition comprising:
(a) 10 to 50 wt. % vegetable lipids based on dry weight of the composition,
(b) 0.5 to 10 wt. % phospholipids based on total lipid,
(c) glycosphingolipids and
(d) cholesterol,
wherein the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising the phospholipids, the lipid globules having:
(i) a volume-weighted mode diameter between 1.0 and 10 μm, and/or
(ii) a diameter of 2 to 12 μm in an amount of at least 45 volume % based on total lipid,

wherein the core comprises at least 90 wt. % triglycerides having fatty acids and the composition comprises glycerophospholipids having fatty acids derived from milk, and
wherein the composition comprises linoleic acid (LA) in an amount between 5 and 15 wt. % based on total fatty acid.

2. The method according to claim 1 , wherein the lipid globules have a diameter of 2 to 12 μm in an amount of at least 55 volume % based on total lipid.

3. The method according to claim 2 , wherein the lipid globules have:
(i) a volume-weighted mode diameter between 3.0 and 8.0 μm, and/or
(ii) a diameter of 2 to 12 μm in an amount of at least 65 volume % based on total lipid.

4. The method according to claim 1 , wherein the composition comprises n3 LC-PUFA in an amount of 0.2 to 15 wt. % based on total fatty acid.

5. The method according to claim 1 , wherein the composition comprises DHA in an amount of 0.1 to 0.6 wt. % based on total fatty acid.

6. The method according to claim 1 , wherein the composition comprises n6 LC-PUFA in an amount of 0.02 to 5 wt. % based on total fatty acid.

7. The method according to claim 1 , wherein the composition comprises ARA in an amount of 0.1 to 0.6 wt. % based on total fatty acid.

8. The method according to claim 1 , wherein the nutritional composition comprises linoleic acid (LA) and alpha-linolenic acid (ALA) in a weight ratio LA:ALA between 4:1 and 7:1.

9. The method according to claim 1 , wherein brain membrane fluidity is increased.

10. A method for amelioration of cognitive performance in a human subject above 36 months of age, the method comprising administering to the human subject at an age between 0 and 36 months 80 to 2500 ml daily for at least 5 days a nutritional composition comprising:
(a) 10 to 50 wt. % vegetable lipids based on dry weight of the composition,
(b) 0.5 to 10 wt. % phospholipids based on total lipid,
(c) glycosphingolipids and
(d) cholesterol,
wherein the composition comprises lipid globules with a core comprising the vegetable lipids and a coating comprising the phospholipids, the lipid globules having:
(i) a volume-weighted mode diameter between 1.0 and 10 μm, and/or
(ii) a diameter of 2 to 12 μm in an amount of at least 45 volume % based on total lipid,

wherein the core comprises at least 90 wt. % triglycerides having fatty acids and the composition comprises glycerophospholipids having fatty acids derived from milk, and
wherein the composition comprises linoleic acid (LA) in an amount between 5 and 15 wt. % based on total fatty acid.

11. The method according to claim 10 , wherein the composition comprises n3 LC-PUFA in an amount of at least 0.2 wt. % based on total fatty acid and that does not exceed 15 wt. % based on total fatty acid.

12. The method according to claim 10 , wherein the composition comprises DHA in an amount of 0.1 to 0.6 wt. % based on total fatty acid.

13. The method according to claim 10 , wherein the composition comprises n6 LC-PUFA in an amount of at least 0.02 wt. % based on total fatty acid and that does not exceed 5 wt. % based on total fatty acid.

14. The method according to claim 10 , wherein the composition comprises ARA in an amount of 0.1 to 0.6 wt. % based on total fatty acid.

15. The method according to claim 10 , wherein the nutritional composition comprises linoleic acid (LA) and alpha-linolenic acid (ALA) in a weight ratio LA:ALA between 4:1 and 7:1.

16. The method according to claim 1 , wherein the administration occurs when the human subject is between 0 and 36 months of age.

17. The method according to claim 16 , wherein the brain membrane n3 LC-PUFA and/or brain membrane DHA is increased when the human subject has reached an age above 36 months.

18. The method according to claim 17 , wherein the brain membrane n3 LC-PUFA and/or brain membrane DHA is increased when the human subject has reached an age above 5 years.

19. The method according to claim 1 or 10 , wherein all polar lipids are derived from milk, wherein polar lipids are the sum of phospholipids, glycosphingolipids and cholesterol.

20. The method according to claim 1 or 10 , wherein the milk is milk of cows, mares, sheep, goats, buffalos, horses and/or camels.

21. The method according to claim 19 , wherein the milk is milk of cows, mares, sheep, goats, buffalos, horses and/or camels.

22. The method according to claim 1 or 10 , wherein the composition further comprises non-digestible oligosaccharides with a degree of polymerization between 2 and 250.

Assignees

• Van Der Beek Eline Marleen
• Abrahamse-Berkeveld Marieke
• Schipper Annemiek Lidewij
• Speelmans Gelske
• Nutricia Nv

Inventors

• Van Der Beek Eline Marleen
• Abrahamse-Berkeveld Marieke
• Schipper Annemiek Lidewij
• Speelmans Gelske

Classifications

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61P25/24

  Antidepressants · CPC title

• A61P25/32

  Alcohol-abuse · CPC title

• A61P25/22

  Anxiolytics · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title